Bayer, the German Pharmaceutics company, has applied this Monday to acquire an authorization to have its drug Regorafenib in the market. After all liver cancer patients successfully finish the clinical trials, Bayer can get the approval of the second-line treatment.
This new drug is complemental for Stivarga, a medicine that treats colorectal cancer (mCRC) and gastrointestinal stromal tumors already. Worldwide almost 800,000 people are diagnosed with Hepatocellular carcinoma per year, and it has been increasing. Just in the United States, the incidence of liver cancer was present in over 39,000 cases, and that number has tripled since 1980s average. Globally, liver related cancer is the second deadliest type of cancer.
“For nearly a decade and counting, Bayer has been committed to meeting the needs of those with liver cancer with our proven first-line systemic therapy in unresectable HCC patient’s therapy, Nexavar,” said Dario Mirski, M.D., Bayer’s senior vice president and head of medical affairs for the Americas. “Clearly, more options are needed for these patients, especially in the second-line setting. The filing of Stivarga in HCC demonstrates our commitment to ongoing research in this difficult-to-treat cancer.”
About Regorafenib and Hepatocellular Carcinoma
Today, Hepatocellular carcinoma (HCC) represents about 75%-80% of liver cancer cases around the world. This type of cancer is the fifth most common among men and ninth among women globally, and the Western Pacific Area is the most affected area, with over 500,000 cases nowadays. Just four years ago, over 746,000 people died because of liver cancer.
The U.S. Food and Drug Administration Office granted Stivarga the “Fast Track” designation. This is a mechanism designed to accelerate the development and expedite the review of drugs in cases related to life-threating diseases. It needs to be considered on this matter that the tolerability and safety that this medicine gives to the consumers use to be highly consistent.
Right now in the US, Stivarga (Regorafenib first line treatment) is indicated for patients with severe and advanced cases of colorectal cancer, which were previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. Also, it is recommended to patients with metastatic gastrointestinal stromal tumor (GIST). In order for this medicine to be appropriate, the patient must have been under the treatment of imatinib mesylate and sunitinib malate.
Source: PR Newswire
One thought on “Bayer applies for authorization to sell Regorafenib for liver cancer treatment”
Here is my story. greatful
My wife was diagnosed with a cancer, (
before i learnt of Rick Simpsons oil / RSO ) the hospital said to do
chemotherapy and radiotherapy.. she did.. and went through a lot.. but
no cure, after a while the doctors said the cancer was spreading and we
could look for alternatives.. i searched the internet and found out
about the oil.. asked alot of questions.. watched the videos etc.. we
made the oil our selves but it couldn’t just work out we were doing more
harm than good and the cancer was still there spreading, i searched
more on the internet i found a testimony on how a lady got the oil via
an email, email@example.com immediately copied the
email: i wrote to this very email firstname.lastname@example.org
and in an hour later i got a reply back asking me some few questions,
and enlightened me on how to get the oil in the next 48hours, i placed
my order and in the next 48hours the medication oil got to us.
immediately my wife started using the oil, it been two months now, since
my wife has been using the medication oil and the cancerous problems
are gone this very fact was clarified by the doctor
i put up this
piece of testimony for the sake of those once who need this oil to
please don’t die in silence their is a cure for your cancer today email:
email@example.com and get the oil.